PRELIMINARY REPORT OF THE USE ON ADULTS OF A RECOMBINANT YEAST-DERIVED HEPATITIS B VACCINE MANUFACTURED BY INSTITUTO BUTANTAN

Three 10 µg doses of the recombinant hepatitis B vaccine, manufactured by Instituto Butantan by original technology, were administered in a adult population, mean age 30 years old, following the 0, 1 and 6 months schedule immunization. The clinical trial was considered satisfactory in terms of immun...

Full description

Bibliographic Details
Published in:Revista do Instituto de Medicina Tropical de São Paulo
Main Authors: Angela Aparecida COSTA, Marta INENAMI, Edmundo JUAREZ, Pedro Dorlhiac LLACEN, Isaias RAW
Format: Article in Journal/Newspaper
Language:English
Published: Universidade de São Paulo (USP) 1997
Subjects:
Recombinant hepatitis B vaccine
Clinical trials
Adults
Arctic medicine. Tropical medicine
RC955-962
Infectious and parasitic diseases
RC109-216
Arctic
Online Access:https://doi.org/10.1590/S0036-46651997000100008
https://doaj.org/article/8a0e29a3fea846caaedc141c761b9fec
Description
Summary:Three 10 µg doses of the recombinant hepatitis B vaccine, manufactured by Instituto Butantan by original technology, were administered in a adult population, mean age 30 years old, following the 0, 1 and 6 months schedule immunization. The clinical trial was considered satisfactory in terms of immunogenicity (anti-HBs titers between 17.5-29500 IU/l, seroconversion 95.3%) and reactogenicity (no incapacitating side effects) Três doses de 10 µg da vacina recombinante contra hepatite B, produzida pelo Instituto Butantan, através de tecnologia própria, foram administradas numa população de adultos (idade média 30 anos), seguindo o esquema de imunização 0, 1 e 6 meses após a primeira dose. A avaliação clínica da vacina foi considerada satisfatória em termos de imunogenicidade (títulos dos anticorpos anti-HBs entre 17,5-29500 UI/1, soroconversão 95,3%) e reatividade (sem efeitos colaterais e sintomas clínicos relevantes)

Similar Items